Beigel JH, et al. - This clinical trial executed an investigation of the safety, tolerability, and pharmacokinetics (PK) of radavirsen following single ascending doses and multiple doses, given as IV infusions in healthy adults. The data disclosed that single infusions of radavirsen up to 8 mg/kg, and multi-dosing at 8 mg/kg once daily for 5 days, were safe and well-tolerated in healthy individuals. The multi-dose Day 4 area-under-the-concentration-time curve (AUC_0-24) was comparable to the AUC which correlated with protection from viral infection in a preclinical ferret influenza model.